popular wires

Major broker Goldman Sachs has released a research report outlining reasons why it thinks IGO is a buy and Minera Resources is a sell.

The ASX 200 finished just 0.5 points lower at 7,683, but this was around 44 points below the session's early high. The cause? An ugly CPI!

Want access to commodities of the future? Lowell Resources’ John Forwood & Acorn Capital’s Rick Squire highlight some opportunities.

High inflation reinforces that the RBA should have raised rates by more last year, in line with its peers.

The end to hikes is appealing to many, and this investment type has a history of benefiting from the transition.

Uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts.

The final instalment of The $10,000 Idea Series looks at even more opportunities in the exchange-traded product market.

Is your portfolio adjusted for the modern market? All you need to know with MLC Asset Management’s Anthony Golowenko.

According to these two experts, investors should hold their fire.

A guide to making sense of China's economic data.

A growing cohort of investors are looking to private real estate lending to provide property exposure with less volatility.

Platinum Asset Management’s Clay Smolinski discusses how he’s positioned now, including 10 global stocks and 1 local name

Australian inflation has ticked up - is this a bump in the road or was the end of 2023 the bottom?

Get up to date on overnight market activity and the big events for the day.

Not one, but two potential major takeover rumours did the rounds today as Aussie stocks bounced back, well except for gold stocks, that is.

We test what a poor April means for "Sell in May and go away" and investigate when to buy back if you follow the oldest saying in markets.

The answer lies in interest rates...

Pulsed Field Ablation is the most exciting technology to come to market in many years, and offers great potential returns for the winners

Liquidity risk is often overlooked and can be the silent saboteur of investments. This wire explores how Pella manages that risk.

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of...